共 192 条
[1]
Tannock IF(2004)TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502-1512
[2]
de Wit R(2004)Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 35 1513-1520
[3]
Berry WR(2011)Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 1995-2005
[4]
Horti J(2010)TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 1147-1154
[5]
Pluzanska A(2013)Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer Core Evid 8 27-35
[6]
Chi KN(2013)Radium-223 for the treatment of prostate cancer Expert Opin Investig Drugs 22 379-387
[7]
Petrylak DP(2010)Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411-422
[8]
Tangen CM(2009)Castration-resistant prostate cancer: locking up the molecular escape routes Clin Cancer Res 15 3251-3255
[9]
Hussain MH(2004)Molecular determinants of resistance to antiandrogen therapy Nat Med 10 33-39
[10]
Lara PN(2007)Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells Cancer Invest 25 32-37